Abstract
Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Volume: 10 Issue: 2
Author(s): Yaoyu Chen, Cong Peng, Con Sullivan, Dongguang Li and Shaoguang Li
Affiliation:
Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents
Abstract: Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
Export Options
About this article
Cite this article as:
Chen Yaoyu, Peng Cong, Sullivan Con, Li Dongguang and Li Shaoguang, Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909326
DOI https://dx.doi.org/10.2174/187152010790909326 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design in vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)
Recent Patents on Anti-Cancer Drug Discovery Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Agonists and Antagonists Acting at P2X7 Receptor
Current Topics in Medicinal Chemistry Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry